Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Ecallantide is a recombinant human plasma kallikrein inhibitor used to prevent and treat acute attacks caused by hereditary angioedema. Administration by subcutaneous injection.
As of the last update, we found no published data on its excretion in breast milk.
Its high molecular weight makes it unlikely to be excreted in breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract and is not absorbed (oral bioavailability practically nil), which makes it difficult or impossible for it to pass into infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period, in which there may be greater intestinal permeability.
Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. (Yeich 2023, Bouillet 2015)